Plasma kallikrein inhibitor

The present invention provides compounds of Formula I and pharmaceutical compositions comprising one or more of the compounds, as well as methods of using the compounds to treat or prevent one or more disease states that can benefit from inhibition of plasma kallikrein, such as kallikrein, kallikrein, kallikrein, kallikrein, kallikrein, kallikrein, kallikrein, kallikrein, kallikrein, kallikrein, and kallikrein. Comprise hereditary angioedema, uveitis, posterior uveitis, wet age-related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein. 本发明提供了式I的化合物和包含一种或多种所述化合物的药物组合物，以及使用所述化合物治疗或预防一种或多种疾病状态的方法，所述疾病状态可以受益于血浆激肽释放酶的抑制，包括遗传性血管性水肿、葡萄膜炎、后葡萄膜炎、湿性年龄相关性黄斑水肿、糖尿病性黄斑水肿、糖尿病性视网膜病变和视网膜静脉闭塞。所述化合物是血浆激肽释放酶的选择性抑制剂。